All Neurological disorders articles – Page 4
-
NewsHIV drug Maraviroc could be used to slow glioblastoma growth
Researchers have discovered how seemingly supportive brain cells help glioblastoma thrive, whilst identifying an existing HIV drug, Maraviroc, that could be repurposed to slow tumour growth.
-
ArticleTargeting inflammatory cell death to tackle relapse in AML
Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.
-
NewsHow ageing cells affect brain development and neurodegeneration
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
-
NewsNew Alco5 platform could advance cancer antibody therapies
Biotech company, Tubulis, has published preclinical data on its Alco5 antibody-drug conjugate platform, demonstrating the ability to link antibodies with previously inaccessible hydroxy-containing drugs.
-
NewsVirus-mimicking LENN nanoparticles deliver mRNA to bladder cancer cells
Researchers have developed virus-inspired LENN nanoparticles that deliver mRNA therapies directly to bladder cancer cells, remain stable after freeze-drying and avoid triggering immune responses.
-
NewsScientists develop synthetic bacteriophages to fight drug-resistant bacteria
Scientists have developed the first fully synthetic method for building and reprogramming bacteriophages, offering a faster and safer route to designing virus-based treatments for drug-resistant bacteria.
-
NewsBeige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
-
ArticleDisrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
-
NewsNew TECHNO platform enables large-scale human gene integration in mice
Japanese researchers have developed a new gene-editing platform, TECHNO, that allows entire human genes – including regulatory regions – to be inserted into mice, allowing for better disease modelling and drug testing.
-
NewsClaudin 18.2-targeted therapy advances GI cancer treatment
A novel imaging-guided radiopharmaceutical targeting claudin 18.2 has shown that it can precisely detect and effectively treat gastric and pancreatic tumours, completely eradicating cancer in some preclinical models.
-
ArticleRethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
-
Article2026: the year AI stops being optional in drug discovery
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
-
NewsNew fluorescent technology tracks drug responses in cells
Researchers have developed new innovative fluorescent labels that allow scientists to observe cellular processes with unprecedented clarity – offering a powerful tool for medicine, drug research and cell biology.
-
NewsFunctional retinal organoids improve drug testing for eye disease
Researchers have developed vascularised human retinal organoids featuring the first fully functional light-signal pathways in lab-grown human retina models, opening new possibilities for studying eye disease and testing therapies.
-
Newsinsitro expands AI drug discovery with CombinAbleAI acquisition
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
-
NewsNew study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
-
ArticleAI steps into drug safety: predicting liver injury earlier than ever before
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
-
NewsRare sugars point to future therapies for alcohol dependence
Researchers have identified a biological pathway linking sugar and appetite for alcohol, suggesting that rare sugars could one day form the basis of new therapies and approaches for reducing alcohol consumption and treating dependence.
-
NewsMagnetic stimulation advances heart organoids for future therapies
Researchers have shown that applying magnetic forces to lab-grown human heart organoids enhances their maturation and vascular development, offering a more realistic model of early heart formation and the possibility of future cardiac therapies.
-
NewsSchrödinger partners with Lilly TuneLab on AI drug discovery
Schrödinger has announced a collaboration with Eli Lilly’s TuneLab platform, integrating advanced AI-driven drug discovery workflows into its LiveDesign enterprise informatics system.